Answers to Everyday Practice Challenges in HIV Medicine:
A Phone-a-Friend Peer Consult Series—Volume 3
Early experience implementing long-acting injectable cabotegravir/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-funded clinic in the US South.
Collins LF, Corbin-Johnson D, Asrat M, et al. Open Forum Infect Dis. 2022;9(9):ofac455.
48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.
Hickey MD, Gistand N, Grochowski J, et al. Clin Infect Dis. 2025;80(4):864-870.
Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359.
Rana AI, Bao Y, Zheng L, et al. Conference on Retroviruses and Opportunistic Infections; March 3-6, 2024; Denver, CO. Abstract 212.
CLINICAL PRACTICE GUIDELINES
Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel.
Gandhi RT, Landovitz RJ, Sax PE, et al. JAMA. 2024. [Epub ahead of print]
Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel.
Sax PE, Thompson MA, Saag MS; IAS-USA Treatment Guidelines Panel. JAMA. 2024;331(12):1060-1061.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
CLINICIAN RESOURCES
Clinical Guidelines Program: HIV Treatment
New York State Department of Health AIDS Institute
Clinician-to-Clinician Advice
National Clinician Consultation Center; University of California, San Francisco
Recommendations
US Preventive Services Task Force.
PATIENT AND CAREGIVER RESOURCES
AIDSMap
NAM Publications
Living with HIV
Centers for Disease Control and Prevention
